Skip to main content

Roche Holding Ltd ADR(RHHBY)
OTC US

Today's Change
Delayed Last Update
Day Low51.0400
Day High51.4200
Open:51.1050
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding (OtherRHHBY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)
Tipranks
Jefferies Reaffirms Their Sell Rating on Roche Holding AG (RHHVF)
Zacks Investment Research
AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
GlobeNewswire
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
Tipranks
3 Best Vanguard Dividend ETFs for Reliable Passive Income in 2026
Zacks Investment Research
Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
Motley Fool
Could AbbVie Crash Lilly's Weight‑Loss Party?
Tipranks
UBS Remains a Buy on Roche Holding AG (RHHVF)
GlobeNewswire
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Tipranks
Analysts Offer Insights on Healthcare Companies: Roche Holding (OtherRHHBY), Nutriband (NTRB) and REPRO-MED Systems (KRMD)
Zacks Investment Research
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
Tipranks
VYMI vs. VIG vs. VYM: Which Vanguard Dividend ETF Pays You Most?
Zacks Investment Research
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
Zacks Investment Research
The Zacks Analyst Blog Roche Holding, AT&T and Amgen
The Zacks Analyst Blog Roche Holding, AT&T and Amgen
Zacks Investment Research
Top Stock Reports for Roche, AT&T & Amgen
Top Stock Reports for Roche, AT&T & Amgen
Zacks Investment Research
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
Zacks Investment Research
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Motley Fool
Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF
Motley Fool
The Best Healthcare Stocks to Buy With $50 Right Now
Tipranks
Roche Boosts AI Infrastructure with Additional Nvidia Chips, Stock Rises
Zacks Investment Research
Can Merck's New Drugs & Pipeline Ease Keytruda LOE Concerns?
Can Merck's New Drugs & Pipeline Ease Keytruda LOE Concerns?
Motley Fool
Is Eli Lilly's Weight Loss Empire in Trouble?
Tipranks
Berenberg Bank Remains a Hold on Roche Holding (RHHBY)
Tipranks
J.P. Morgan Reaffirms Their Hold Rating on Roche Holding AG (RHHVF)
Tipranks
Barclays Remains a Buy on Roche Holding AG (RHHVF)
MarketBeat
3 ETFs to Avoid as Oil Shock Hits Markets
MarketBeat.com
Tipranks
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02
Tipranks
Roche Holding AG (RHHVF) Gets a Buy from Bernstein
Motley Fool
2 Underrated Weight Loss Stocks to Buy Now
Tipranks
J.P. Morgan Sticks to Its Hold Rating for Roche Holding AG (RHHVF)
Zacks Investment Research
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Tipranks
Barclays Keeps Their Buy Rating on Roche Holding AG (RHHVF)

Profile

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.